Literature DB >> 8124670

Central nervous system imaging in reevaluation of patients with neurofibromatosis type 1.

P Balestri1, L Calistri, R Vivarelli, G Bartalini, L Mancini, A Berardi, A Fois.   

Abstract

We report the results of the reevaluation of 24 patients with neurofibromatosis type 1 (NF1) using central nervous system (CNS) imaging techniques. The first examination by computed tomography (CT) or magnetic resonance imaging (MRI) indicated the presence of optic glioma in three cases, "unidentified bright objects" (UBOs) in six, and a suspected right frontal tumor in one. In two patients optic glioma and UBOs were both present and in one of them a bulbar tumor was also suspected. Later imaging examinations revealed the appearance of optic glioma in three more cases and UBOs in nine. In two of these patients both optic glioma and UBOs were present. This study indicates that the likelihood of detecting imaging abnormalities in patients with NF1 increases when systematic follow-up is performed. Optic gliomas are characteristic of pediatric patients; they rarely give rise to clinical manifestations (1/6 cases) and in general progress very slowly. For these reasons, therapeutic strategy must be carefully considered and individually decided. UBOs are very frequent findings in pediatric patients with NF 1 and therefore they must be considered diagnostically relevant. They are not related to clinical manifestations and spontaneous regression has been observed. The nature of these imaging abnormalities is still unknown, but because they do not behave like tumors, useless and dangerous therapeutic procedures should not be employed.

Entities:  

Mesh:

Year:  1993        PMID: 8124670     DOI: 10.1007/bf00393546

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  15 in total

1.  [Neuro-imaging and neurofibromatosis].

Authors:  J Zeller
Journal:  Ann Dermatol Venereol       Date:  1990       Impact factor: 0.777

2.  Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference.

Authors: 
Journal:  Arch Neurol       Date:  1988-05

3.  Multifocal intracranial MR abnormalities in neurofibromatosis.

Authors:  R W Hurst; S A Newman; W S Cail
Journal:  AJNR Am J Neuroradiol       Date:  1988 Mar-Apr       Impact factor: 3.825

4.  Neurofibromatosis types 1 and 2: cranial MR findings.

Authors:  S Aoki; A J Barkovich; K Nishimura; B O Kjos; T Machida; P Cogen; M Edwards; D Norman
Journal:  Radiology       Date:  1989-08       Impact factor: 11.105

5.  Cranial MR imaging in patients with von Recklinghausen's disease (neurofibromatosis type I).

Authors:  T Hashimoto; M Tayama; M Miyazaki; Y Kuroda; K Hiura; K Hujino; K Yamashita
Journal:  Neuropediatrics       Date:  1990-11       Impact factor: 1.947

Review 6.  Optic pathway gliomas in neurofibromatosis.

Authors:  D W Dunn; V Purvin
Journal:  Dev Med Child Neurol       Date:  1990-09       Impact factor: 5.449

7.  Summary of patient data from a multidisciplinary neurofibromatosis clinic.

Authors:  E K Schorry; D W Stowens; A H Crawford; P A Stowens; W R Schwartz; P S Dignan
Journal:  Neurofibromatosis       Date:  1989

8.  The significance of MRI abnormalities in children with neurofibromatosis.

Authors:  P K Duffner; M E Cohen; F G Seidel; D W Shucard
Journal:  Neurology       Date:  1989-03       Impact factor: 9.910

9.  Optic gliomas in children with neurofibromatosis type 1.

Authors:  R Listernick; J Charrow; M J Greenwald; N B Esterly
Journal:  J Pediatr       Date:  1989-05       Impact factor: 4.406

10.  Optic gliomas in children with neurofibromatosis type 1.

Authors:  A M Lund; F Skovby
Journal:  Eur J Pediatr       Date:  1991-10       Impact factor: 3.183

View more
  4 in total

1.  New strategies in pediatric gliomas: molecular advances in pediatric low-grade gliomas as a model.

Authors:  Eric Raabe; Mark W Kieran; Kenneth J Cohen
Journal:  Clin Cancer Res       Date:  2013-07-23       Impact factor: 12.531

2.  Fatal glioblastoma multiforme in a patient with neurofibromatosis type I: the dilemma of systematic medical follow-up.

Authors:  Felix Distelmaier; Raimund Fahsold; Guido Reifenberger; Martina Messing-Juenger; Jörg Schaper; Dominik T Schneider; Ulrich Göbel; Ertan Mayatepek; Thorsten Rosenbaum
Journal:  Childs Nerv Syst       Date:  2006-08-29       Impact factor: 1.475

3.  Cerebral glucose metabolism in neurofibromatosis type 1 assessed with [18F]-2-fluoro-2-deoxy-D-glucose and PET.

Authors:  P Balestri; G Lucignani; A Fois; L Magliani; L Calistri; C Grana; R M Di Bartolo; D Perani; F Fazio
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-12       Impact factor: 10.154

4.  Clinical sensitivity and specificity of multiple T2-hyperintensities on brain magnetic resonance imaging in diagnosis of neurofibromatosis type 1 in children: diagnostic accuracy study.

Authors:  Zlatko Sabol; Biserka Resić; Romana Gjergja Juraski; Filip Sabol; Matilda Kovac Sizgorić; Kresimir Orsolić; David Ozretić; Dubravka Sepić-Grahovac
Journal:  Croat Med J       Date:  2011-08-15       Impact factor: 1.351

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.